Catalog Pro5® MHC Class I PentamersPentamers by Research Area
Adenovirus
|
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*01:01 |
686 |
TDLGQNLLY |
A |
Adenovirus 5 Hexon 886-894 |
A*24:02 |
684 |
TYFSLNNKF |
A |
Adenovirus 5 Hexon 37-45 |
B*07:02 |
989 |
KPYSGTAYNAL |
A |
Adenovirus Hexon 114-124 |
Autoimmunity
Publications citing AutoImmunity Pentamers
Case studies of Customer
Research into AutoImmunity
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
151 |
KLQVFLIVL |
A |
T1D Diabetes human prepro islet amyloid polypeptide ppIAPP 5-13 |
A*02:01 |
954 |
LNIDLLWSV |
A |
T1D Diabetes IGRP 228–236 |
A*02:01 |
851 |
HLVEALYLV |
A |
Insulin B chain 10-18 |
A*02:01 |
393 |
VMNILLQYV |
A |
GAD65 114-122 |
A*02:01 |
470 |
SLSRFSWGA |
A |
Myelin basic protein 110-118 |
A*02:01 |
1904 |
VLFGLGFAI |
A |
T1D Diabetes IGRP 265-273 |
Cancer
Publications Citing Cancer Pentamers
Case Studies of Customer
Research into Cancer
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*01:01 |
307 |
KSDICTDEY |
A |
Tyrosinase 243-251 (244S) |
A*02:01 |
2291 |
AILALLPAL |
A |
Prostate Stem Cell Antigen (PSCA) 105-133 |
A*02:01 |
1920 |
ALLTSRLRFI |
A |
Telomerase Reverse Transcriptase (hTRT) 615-624 |
A*02:01 |
2083 |
FLAEDALNTV |
A |
Epithelial Discoidin Domain Receptor 1 (EDDR1) 867-876 |
A*02:01 |
2079 |
FLYDDNQRV |
A |
Topoisomerase II-alpha-b 828-836 |
A*02:01 |
1386 |
GLAPPQHLIRV |
A |
p53 187-197 |
A*02:01 |
468 |
ILSLELMKL |
A |
Receptor for hyaluronic
acid–mediated
|
A*02:01 |
1464 |
LTLGEFLKL |
A |
Survivin-3A 96-104 |
A*02:01 |
2299 |
SLPPPGTRV |
A |
p53 149-157 |
A*02:01 |
1403 |
VIMPCSWWV |
A |
Chondromodulin-I 319-327 |
A*02:01 |
1201 |
YMCSFLFNL |
A |
Ewing Tumor EZH2 666-674 |
A*02:01 |
061 |
YMDGTMSQV |
A |
Tyrosinase 369-377 (371D) |
A*02:01 |
447 |
YLQVNSLQTV |
A |
Telomerase Reverse Transcriptase (hTRT) 988-997 |
A*02:01 |
859 |
KLQDASAEV |
A |
HM1.24-aa 126-134 |
A*02:01 |
329 |
ILLWQPIPV |
A |
Prostatic Acid Phosphatase-3 (PAP-3) 135-143 |
A*02:01 |
560 |
GLMEEMSAL |
A |
Human Mena protein (overexpressed in breast cancer) |
A*02:01 |
813 |
FVGEFFTDV |
A |
GPC3 144-152 (overexpressed in hepatocellular carcinoma) |
A*02:01 |
075 |
YLSGANLNL |
S |
Carcinogenic Embryonic Antigen (CEA) 571-579 |
A*02:01 |
157 |
VLYRYGSFSV |
A |
gp100 (pmel17) 476-485 |
A*02:01 |
250 |
VLQELNVTV |
S |
Leukocyte Proteinase-3 (Wegener's autoantigen) 169-177 |
A*02:01 |
097 |
VISNDVCAQV |
A |
Prostate Specific Antigen-1 (PSA-1) 154-163 |
A*02:01 |
390 |
SLLMWITQV |
A |
NY-ESO-1 157-165 |
A*02:01 |
212 |
RLLQETELV |
S |
HER-2/neu 689-697 |
A*02:01 |
810 |
LIAHNQVRQV |
A |
HER-2/neu 85–94 |
A*02:01 |
690 |
LLHETDSAV |
A |
PSMA/PSM-P1 4-12 |
A*02:01 |
599 |
ALDVYNGLL |
A |
Prostatic acid phosphatase precursor (PAP) 299-307 |
A*02:01 |
645 |
YLNTVQPTCV |
A |
EGF-R 1138-1147 |
A*02:01 |
781 |
VLDGLDVLL |
A |
PRAME 100-108 |
A*02:01 |
689 |
VLAGGFFLL |
A |
PSMA 27-38 |
A*02:01 |
394 |
YLFFYRKSV |
A |
mTERT 572-580 |
A*02:01 |
034 |
FLWGPRALV |
A |
MAGEA3 271-279 |
A*02:01 |
646 |
KLFGTSGQKT |
A |
EGF-R-479 350-359 |
A*02:01 |
915 |
TLPGYPPHV |
A |
PAX-5 311-319 |
A*02:01 |
1056 |
SLFLGILSV |
A |
CD20 188-196 (B cell malignancies) |
A*02:01 |
117 |
RLVDDFLLV |
A |
Telomerase Reverse Transcriptase 865-873 |
A*02:01 |
208 |
LLLLTVLTV |
A |
MUC-1 12-20 |
A*02:01 |
205 |
LLGRNSFEV |
A |
p53 264-272 |
A*02:01 |
600 |
ALFDIESKV |
A |
PSM P2 (prostate) |
A*02:01 |
1013 |
FLGYLILGV |
A |
Prostatic Acid Phosphatase-3 (PAP-3) |
A*02:01 |
561 |
TMNGSKSPV |
A |
hMena 502-510 |
A*02:01 |
391 |
LMLGEFLKL |
S |
Survivin 96-104 |
A*02:01 |
338 |
QLCPICRAPV |
A |
Livin/ML-IAP280 175-184 |
A*02:01 |
1181 |
SLSEKTVLL |
A |
CD59 glycoprotein precursor 106-114 |
A*02:01 |
958 |
SLVDVMPWL |
A |
Cytochrome p450 1B1 239-248 |
A*02:01 |
214 |
KIFGSLAFL |
A |
HER-2/neu 369-377 |
A*02:01 |
046 |
IMDQVPFSV |
S |
gp100 (pmel17) 209-217 |
A*02:01 |
210 |
ILHNGAYSL |
A |
HER-2/neu 435-443 |
A*02:01 |
085 |
ILAKFLHWL |
S |
Telomerase 540-548 |
A*02:01 |
249 |
HLSTAFARV |
A |
G250 (renal cell carcinoma) 217-225 |
A*02:01 |
125 |
GVLVGVALI |
A |
Carcinogenic Embryonic Antigen (CEA) 694-702 |
A*02:01 |
527 |
ALYVDSLFFL |
A |
PRAME PRA 300–309 |
A*02:01 |
405 |
KLQCVDLHV |
A |
Prostate Specific Antigen 146-154 |
A*02:01 |
086 |
ALQPGTALL |
A |
Prostate Stem Cell Antigen (PSCA) 14-22 |
A*02:01 |
302 |
KVAELVHFL |
A |
MAGEA3 112-120 |
A*02:01 |
057 |
KTWGQYWQV |
A |
gp100 (pmel17) 154-162 |
A*02:01 |
389 |
GLYDGMEHL |
A |
MAGEA-10 254-262 |
A*02:01 |
404 |
FLTPKKLQCV |
A |
Prostate Specific Antigen-1 (PSA-1) 141-150 |
A*02:01 |
082 |
ELAGIGILTV |
s |
MelanA / MART 26-35 |
A*02:01 |
171 |
KVLEYVIKV |
A |
MAGEA1 278-286 |
A*02:01 |
2293 |
GLQHWVPEL |
A |
BA46 (Lactadherin) 97-106 |
A*02:01 |
2294 |
GVRGRVEEI |
A |
bcr-abl fusion protein |
A*02:01 |
048 |
YLSGADLNL |
A |
Carcinoembryonic antigen (CEA)-derived peptide CAP1-6D |
A*02:01 |
2296 |
ITDQVPFSV |
A |
gp100 (pmel) 209-217 |
A*02:01 |
047 |
YLEPGPVTV |
A |
gp100 (pmel) 280-288 (288V) |
A*02:01 |
2301 |
YLQLVFGIEV |
A |
MAGEA2 157-166 |
A*02:01 |
2298 |
KVAEELVHFL |
A |
MAGEA3 112-120 (alternative version) |
A*02:01 |
049 |
SLLMWITQC |
A |
NY-ESO-1 157-165 (9C) |
A*02:01 |
2300 |
YLGSYGFRL |
A |
p53 103-111 |
A*02:01 |
2297 |
KLCPVQLWV |
A |
p53 139-147 |
A*02:01 |
654 |
RMPEAAPPV |
A |
p53 65-73 |
A*02:01 |
1787 |
RLTSRVKAL |
A |
Telomerare Reverse Transcriptase (hTRT) 653-661 |
A*02:01 |
1786 |
GLLGASVLGL |
A |
Telomerase Reverse Transcriptase (hTRT) 674-683 |
A*02:01 |
381 |
LLLTVLTVV |
A |
Tumor Mucin Antigen 13-21 |
A*03:01 |
118 |
ALLAVGATK |
A |
gp100 (pmel17) 17-25 |
A*03:01 |
264 |
ATGFKQSSK |
A |
bcr-abl 210 kD fusion protein 259-269 |
A*03:01 |
087 |
KQSSKALQR |
S |
bcr-abl 210 kD fusion protein 21-29 |
A*03:01 |
541 |
RISTFKNWPK |
A |
Survivin-3A 18-27 (27K) |
A*24:02 |
416 |
EYLQLVFGI |
A |
MAGEA2 156-164 |
A*24:02 |
421 |
TFPDLESEF |
A |
MAGEA3 97-105 |
A*24:02 |
209 |
TYACFVSNL |
A |
Carcinogenic Embryonic Antigen (CEA) 652-660 |
A*24:02 |
417 |
TYLPTNASL |
A |
HER-2/neu 63-71 |
A*24:02 |
418 |
VYGFVRACL |
A |
Telomerase reverse transcriptase (hTRT) 461-469 |
A*24:02 |
230 |
AFLPWHRLF |
A |
Tyrosinase 188-196 |
A*24:02 |
2303 |
CYASGWGSI |
A |
Prostate Specific Antigen-1 153-161 |
A*24:02 |
238 |
VYFFLPDHL |
A |
gp100-intron 4 170-178 |
A*24:02 |
1806 |
RYCNLEGPPI |
A |
Lymphocyte antigen 6 complex locus K (LY6K) 177-186 |
A*24:02 |
2302 |
AYACNTSTL |
A |
Survivin 80-88 |
B*07:02 |
2304 |
LPWHRLFLL |
A |
Tyrosinase 208-216 |
B*08:01 |
094 |
GFKQSSKAL |
A |
bcr-abl 210 kD fusion protein 19-27 |
B*35:01 |
2307 |
MPFATPMEA |
A |
NY-ESO-1 94-102 |
H-2 Db |
1731 |
ATFKNWPFL |
A |
Murine Survivin 20-28 |
H-2Db |
695 |
Abu-Abu-L-Abu-LTVFL |
A |
Moloney murine sarcoma virus (MoMSV) GagL 85–93 |
H-2Db |
2199 |
FSNSTNDILI |
A |
VEGFR2/KDR fragment 1 614-624 |
H-2Db |
1333 |
KVPRNQDWL |
A |
gp100 (pmel17) 25-33 |
H-2Kb |
185 |
SVYDFFVWL |
A |
Tyrosinase related protein-2 180-188 |
H-2Kb |
351 |
HNTQYCNL |
A |
MAGEA5 5-12 |
H-2Kb |
2311 |
TVSEFLKL |
A |
Murine Survivin 97-104 |
H-2Kd |
0275 |
DYWGQGTEL |
A |
Surface IgG (sA20-Ig) of A20 106-114 |
H-2Kd |
814 |
EYILSLEEL |
A |
GPC3 298-306 |
H-2Kd |
343 |
TYVPANASL |
A |
neu/HER-2/Erbb2 proto-oncoprotein 66-74 |
H-2Ld |
150 |
LPYLGWLVF |
A |
Tumour Antigen P815 35-43 |
Chlamydia
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
334 |
RLNMFTPYI |
A |
Chlamydia trachomatis MOMP 258-266 |
CMV
Publications citing CMV Pentamers
Case Studies of Customer Research
into CMV
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*01:01 |
739 |
VTEHDTLLY |
A |
HCMV pp50 245-253 |
A*01:01 |
266 |
YSEHPTFTSQY |
A |
HCMV pp65 363-373 |
A*02:01 |
1598 |
VLAELVKQI |
A |
HCMV IE1 81-89 |
A*02:01 |
008 |
NLVPMVATV |
S |
HCMV pp65 495-504 |
A*03:01 |
1599 |
KLGGALQAK |
A |
HCMV IE1 184-192 |
A*24:02 |
414 |
QYDPVAALF |
A |
HCMV pp65 341-349 |
A*24:02 |
380 |
VYALPLKML |
A |
HCMV pp65 113-121 |
B*07:02 |
045 |
TPRVTGGGAM |
S |
HCMV pp65 417-426 |
B*07:02 |
308 |
RPHERNGFTVL |
A |
HCMV pp65 265-275 |
B*08:01 |
691 |
QIKVRVDMV |
A |
HCMV IE1 88-96 |
B*35:01 |
114 |
IPSINVHHY |
A |
HCMV pp65 123-131 |
H-2Db |
2313 |
HGIRNASFI |
A |
MCMV m45 985-993 |
H-2Dd |
278 |
AGPPRYSRI |
A |
MCMV m164 257-265 |
H-2Ld |
021 |
YPHFMPTNL |
S |
MCMV IE1 168-176 |
EBV
Publications citing EBV Pentamers
Case Studies of Customer Research
into EBV
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
666 |
FLYALALLL |
A |
EBV LMP-2 356-364 |
A*02:01 |
001 |
GLCTLVAML |
S |
EBV BMLF-1 259-267 |
A*02:01 |
042 |
CLGGLLTMV |
S |
EBV LMP-2 426-434 |
A*02:01 |
409 |
YLLEMLWRL |
A |
EBV LMP-1 125-133 |
A*02:01 |
2292 |
FLDKGTYTL |
A |
EBV BALF-4 276–284 |
A*03:01 |
727 |
RLRAEAQVK |
A |
ENV EBNA 3A 603–611 |
A*11:01 |
639 |
ATIGTAMYK |
A |
EBV BRLF1 134-142 |
A*11:01 |
199 |
IVTDFSVIK |
A |
EBV EBNA-4 416-424 |
A*11:01 |
508 |
SSCSSCPLSK |
A |
EBV LMP-2 340-349 |
A*24:02 |
648 |
PYLFWLAAI |
A |
EBV LMP2 131-139 |
A*24:02 |
683 |
TYGPVFMSL |
A |
EBV LMP2 419–427 |
A*24:02 |
420 |
TYGPVFMCL |
A |
EBV LMP-2 419-427 |
B*07:02 |
044 |
RPPIFIRRL |
S |
EBV EBNA-3A 247-255 |
B*07:02 |
2305 |
QPRAPIRPI |
A |
EBV EBNA-3C 881-889 |
B*08:01 |
190 |
RAKFKQLL |
S |
EBV BZLF-1 190-197 |
B*08:01 |
073 |
FLRGRAYGL |
S |
EBV EBNA-3A 193-201 |
B*08:01 |
489 |
QAKWRLQTL |
A |
EBV EBNA3A 158-166 |
B*35:01 |
387 |
HPVGEADYFEY |
A |
EBV EBNA-1 407-417 |
B*35:01 |
399 |
EPLPQGQLTAY |
A |
EBV BZLF-1 54-64 |
B*40:01 |
692 |
IEDPPFNSL |
A |
EBV LMP2 200-208 |
HBV
Publications citing HBV Pentamers
Case Studies of Customer
Research into Hepatitis
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
032 |
FLLSLGIHL |
S |
HBV polymerase 573-581 |
A*02:01 |
027 |
FLLTRILTI |
S |
HBV envelope 183-191 |
A*02:01 |
023 |
FLPSDFFPSV |
S |
HBV core antigen 18-27 |
A*02:01 |
028 |
GLSPTVWLSV |
A |
HBV surface antigen 185-194 |
A*02:01 |
031 |
WLSLLVPFV |
S |
HBV surface antigen 172-181 |
A*02:01 |
283 |
FLPSDFFPSI |
A |
HBV core 18-27 (subtype ADR4) |
A*11:01 |
377 |
YVNVNMGLK |
A |
HBV core antigen 88-96 |
A*24:02 |
413 |
KYTSFPWLL |
A |
HBV polymerase 756-764 |
A*24:02 |
378 |
EYLVSFGVW |
A |
HBV core 117-125 |
H-2Kb |
422 |
ILSPFLPLL |
A |
HBV surface antigen 208-216 |
H-2Kb |
1431 |
MGLKFRQL |
A |
HBV core 93-100 |
H-2Kb |
477 |
VWLSVIWM |
A |
HBV Surface antigen 190-197 |
H-2Ld |
129 |
IPQSLDSWWTSL |
S |
HBV surface antigen 28-39 |
HCV
Publications citing HCV Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*01:01 |
1066 |
ATDALMTGF |
A |
HCV NS3 1436-1444 |
A*01:01 |
740 |
ATDALMTGY |
A |
HCV NS3 1435-1443 |
A*02:01 |
036 |
VLSDFKTWL |
A |
HCV NS5a 1987-1995 |
A*02:01 |
172 |
LLFNILGGWV |
A |
HCV NS4b 1807-1816 |
A*02:01 |
242 |
KLSGLGINAV |
A |
HCV NS3 1406-1415 |
A*02:01 |
1094 |
GLQDCTMLV |
A |
HCV NS5B 2727-2735 |
A*02:01 |
003 |
CINGVCWTV |
A |
HCV NS3 1073-1081 |
A*02:01 |
004 |
YLLPRRGPRL |
A |
HCV core 35-44 |
A*02:01 |
002 |
DLMGYIPAV |
S |
HCV core 132-140 |
A*02:01 |
491 |
DLMGYIPLV |
A |
HCV core 132-140 |
A*02:01 |
040 |
KLVALGINAV |
A |
HCV NS3 1406-1415 |
A*02:01 |
858 |
CVNGVCWTV |
A |
HCV NS3 1073-1081 |
A*02:01 |
037 |
ALYDVVTKL |
A |
HCV NS5b 2594-2602 |
A*03:01 |
035 |
RVCEKMALY |
A |
HCV NS5B 2588-2596 |
A*24:02 |
415 |
AYSQQTRGL |
A |
HCV NS3 1031-1039 |
B*07:02 |
845 |
DPRRRSRNL |
A |
HCV core 111-119 |
B*07:02 |
742 |
GPRLGVRAT |
A |
HCV core 41-49 |
B*08:01 |
721 |
HSKKKCDEL |
A |
HCV NS3 1395-1403 |
B*35:01 |
565 |
HPNIEEVAL |
A |
HCV NS3 1359-1367 |
B*35:01 |
942 |
CPNSSIVY |
A |
HCV E1 207-214 |
B*40:01 |
939 |
REISVPAEIL |
A |
HCV NS5a 2266-2275 |
H-2Db |
791 |
GAVQNEVTL |
A |
HCV NS3 1629-1637 |
HIV
Publications citing HIV Pentamers
Case Studies of Customer Research
into HIV
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
430 |
GLADQLIHL |
A |
HIV-1 Vif 101-109 |
A*02:01 |
799 |
LTFGWCFKL |
A |
HIV-1 Nef 137-145 |
A*02:01 |
084 |
ILKEPVHGV |
S |
HIV-1 RT 476-484 |
A*02:01 |
246 |
KLTPLCVTL |
A |
HIV-1 env gp120 90-98 |
A*02:01 |
010 |
SLYNTVATL |
S |
HIV-1 gag p17 76-84 |
A*02:01 |
174 |
TLNAWVKVV |
A |
HIV-1 gag p24 19-27 |
A*03:01 |
194 |
RLRPGGKKK |
S |
HIV-1 gag p17 19-27 |
A*03:01 |
109 |
QVPLRPMTYK |
S |
HIV-1 nef 73-82 |
A*24:02 |
419 |
RYLKDQQLL |
A |
HIV-1 gag gp41 67-75 |
A*24:02 |
411 |
RYPLTFGWCY |
A |
HIV-1 Nef 134-143 |
B*07:02 |
257 |
TPGPGVRYPL |
S |
HIV-1 nef 128-137 |
B*07:02 |
196 |
IPRRIRQGL |
A |
HIV-1 env gp120 848-856 |
B*07:02 |
877 |
GPGHKARVL |
A |
HIV gag p24 223–231 |
B*08:01 |
193 |
FLKEKGGL |
S |
HIV-1 nef 90-97 |
B*08:01 |
195 |
GEIYKRWII |
A |
HIV-1 gag p24 261-269 |
B*15:01 |
1072 |
RLRPGGKKKY |
A |
HIV-1 p17 20-29 |
B*27:05 |
294 |
KRWIILGLNK |
A |
HIV-1 gag p24 265-274 |
B*27:05 |
874 |
KRWIIMGLNK |
A |
HIV-1 gag p24 263-272 |
B*27:05 |
2306 |
GRAFVTIGK |
A |
HIV-1 gp100 103-111 |
B*35:01 |
255 |
NPDIVIYQY |
A |
HIV-1 RT 328-336 |
B*35:01 |
1211 |
VPLDEDFRKY |
A |
HIV-1 RT 273-282 |
B*40:01 |
840 |
KEKGGLEGL |
A |
HIV-1 Nef 92-100 |
H-2Dd |
177 |
RGPGRAFVTI |
A |
HIV-1 IIIB gp120 318-327 |
H-2Dd |
1684 |
IGPGRAFYA |
A |
HIV-1 US4 gp120 318-326 |
H-2Kd |
176 |
AMQMLKETI |
A |
HIV-1 gag p24 199-207 |
HPV
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
095 |
YMLDLQPETT |
S |
HPV 16 E7 11-20 |
A*02:01 |
2312 |
MLDLQPETT |
A |
HPV 16 E7 12-20 |
A*03:01 |
2064 |
KLCLRFLSK |
A |
HPV 33 E6 64-72 |
B*07:02 |
2065 |
KPTLKEYVL |
A |
HPV 33 E7 5-13 |
H-2Db |
502H |
RAHYNIVTF |
A |
HPV 16 E7 49-57 |
HTLV
Publications citing HTLV Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
200 |
LLFGYPVYV |
A |
Human T-cell lymphotropic virus-1 Tax 11-19 |
A*02:01 |
2309 |
AVLDGLLSL |
A |
HTLV bZIP factor 42-50 |
A*24:02 |
1043 |
SFHSLHLLF |
A |
Human T-cell lymphotropic virus-1 Tax 301-309 |
Influenza
Publications citing Influenza Pentamers
Case Studies of Customer
Research into Influenza
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*01:01 |
076 |
CTELKLSDY |
A |
Influenza A (PR8) NP 44-52 |
A*01:01 |
540 |
VSDGGPNLY |
A |
Influenza A PB1 591-599 |
A*02:01 |
007 |
GILGFVFTL |
S |
Influenza A MP 58-66 |
A*02:01 |
2295 |
ILGFVFTLTV |
A |
Influenza A MP 59-68 |
A*03:01 |
77 |
ILRGSVAHK |
A |
Influenza A (PR8) NP 265-274 |
A*11:01 |
1513 |
SIIPSGPLK |
A |
Influenza A MP 13-21 |
A*11:01 |
1720 |
RMVLASTTAK |
A |
Influenza A MP1 178-187 |
A*11:01 |
1722 |
KSMREEYRK |
A |
Influenza A MP2 70-78 |
B*07:02 |
1744 |
SPIVPSFDM |
A |
Influenza A NP 473-481 |
B*07:02 |
1743 |
QPEWFRNVL |
A |
Influenza A PB1 329-337 |
B*27:05 |
463 |
SRYWAIRTR |
A |
Influenza A NP 383-391 |
H-2Db |
119 |
ASNENMETM |
S |
Influenza A (PR8) NP 366-374 |
H-2Db |
009 |
ASNENMDAM |
S |
Influenza A (NT60) NP 366-374 |
H-2Db |
120 |
SSLENFRAYV |
A |
Influenza A (PR8) Polymerase acidic protein 224-233 |
H-2Kd |
098 |
TYQRTRALV |
S |
Influenza A (PR8) NP 147-155 |
H-2Kd |
240 |
IYSTVASSL |
A |
Influenza A HA 533-541 |
LCMV
Publications citing LCMV Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
2308 |
ALPHIIDEV |
A |
LCMV envelope gp 10-18 |
A*02:01 |
2310 |
YLVSIFLHL |
A |
LCMV envelope gp 447-455 |
H-2Db |
070 |
FQPQNGQFI |
S |
LCMV NP 396-404 |
H-2Db |
069 |
KAVYNFATC |
S |
LCMV GP1 33-41 |
H-2Db |
186 |
SGVENPGGYCL |
A |
LCMV GP 276-286 |
H-2 Kb |
2076 |
ISHNFCNL |
A |
LCMV GP 118-125 |
Listeria
Publications citing Listeria Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
H-2Kd |
178 |
GYKDGNEYI |
A |
Listeria monocytogenes Listeriolysin 91-99 |
Malaria
Publications citing Malaria Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
314 |
YLNKIQNSL |
A |
Plasmodium falciparum CSP 334-342 |
H-2Kd |
771 |
YYIPHQSSL |
A |
Plasmodium falciparum Liver stage antigen 1671-1679 |
H-2Kd |
376 |
SYIPSAEKI |
A |
Plasmodium berghei CSP 252-260 |
miHAg
Publications citing miHAg Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
581 |
RTLDKVLEV |
A |
miHAg HA-8 |
A*02:01 |
175 |
FIDSYICQV |
A |
miHAg H-Y (human SMCY) 311-319 |
A*02:01 |
473 |
VLHDDLLEA |
A |
miHAg HA-1 137-145 |
B*07:02 |
1113 |
SPSVDKARAEL |
A |
miHAg SMCY 1041-1051 |
H-2Db |
328 |
KCSRNRQYL |
A |
miHAg SMCY 738-746 |
H-2Db |
327 |
WMHHNMDLI |
S |
miHAg UTY 246-254 |
Model Antigen
Publications citing Model Antigen Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
H-2Kb |
093 |
SIINFEKL |
S |
Ovalbumin 257-264 |
H-2Kb |
908 |
KVVRFDKL |
A |
Ovalbumin (subdominant) 55-62 |
H-2Kb |
562 |
LTFNYRNL |
A |
Histocompatibility antigen 60 39-46 |
H-2Kb |
1803 |
SIYRYYGL |
A |
Synthetic variant of VSV Nucleoprotein 498–505 |
H-2Kd |
198 |
HYLSTQSAL |
A |
Enhanced Green Fluorescent Protein (eGFP) 200-208 |
H-2Ld |
074 |
TPHPARIGL |
S |
E. coli beta-galactosidase 876-884 |
Negative
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
N01 |
NEGATIVE |
S |
Negative Control |
Other
Publications citing other Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
366 |
LMWYELSKI |
A |
KSHVF-8 gB.492-500 |
A*02:01 |
773 |
VLPLTVAEV |
A |
Mesothelin 530–538 |
A*02:01 |
1152 |
VLMIKALEL |
A |
Non muscle Myosin-9 741-749 |
A*02:01 |
353 |
RILGAVAKV |
A |
Vinculin 822-830 |
A*02:01 |
133 |
LLDVPTAAV |
A |
Interferon gamma inducible protein (GILT) 30 27-35 |
A*02:01 |
1153 |
QLFNHTMFI |
A |
Non-muscle Myosin 478-486 |
E*01:01 |
712 |
VMAPRTLIL |
A |
HLA-C leader sequence peptide |
H-2Kb |
188 |
SSIEFARL |
A |
HSV-1 gp B 498-505 |
H-2Kb |
828 |
KSPWFTTL |
A |
MuLV env 622-629 |
H-2Kb |
488 |
VVYDFLKL |
A |
SV40 T antigen 404-411 |
H-2Kd |
062 |
RYLKNGKETL |
A |
HLA-Cw3 170-179 |
H-2Kd |
458 |
KYNKANVFL |
A |
NRP-V7 superagonist peptide 8.3 Tg NOD mouse |
H-2Ld |
398 |
SPSYVYHQF |
A |
MuLV env gp70 423-431 |
RSV
Publications citing RSV Pentamers
Case Studies of Customer
Research into Viral Diseases
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
801 |
KMLKEMGEV |
A |
RSV NP 137-145 |
H-2Kd |
154 |
SYIGSINNI |
A |
RSV M2 82-90 |
H-2Kd |
149 |
KYKNAVTEL |
A |
RSV A strain F protein 85-93 |
Sendai Virus
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
H-2Kb |
056 |
FAPGNYPAL |
S |
Sendai virus NP 324-332 |
SIV
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
Mamu-A*01 |
1110 |
CTPYDINQM |
A |
SIV Gag 181-189 |
Mamu-A*02 |
1111 |
YTSGPGIRY |
A |
SIV Nef 159-167 |
Mamu-A*02 |
1112 |
GSENLKSLY |
A |
SIV Gag 71-79 |
Trypanosoma
Publications citing Trypanosoma Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
H-2Kb |
964 |
VNHRFTLV |
A |
Trypanosoma cruzi ASP-2 553-560 |
H-2Kb |
708 |
ANYNFTLV |
A |
Trypanosoma cruzi SP 536-543 |
Tuberculosis
Publications citing Tuberculosis Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
324 |
GLPVEYLQV |
A |
Mycobacterium bovis antigen 85-A 6-14 |
A*02:01 |
276 |
KLIANNTRV |
A |
Mycobacterium bovis antigen 85-A 200-208 |
H-2Db |
547 |
AIQGNVTSI |
A |
Mycobacterium tuberculosis ESAT-6 17-25 |
H-2Kb |
769 |
IMYNYPAML |
A |
Mycobacterium tuberculosisTB10.4 4-12 |
H-2Kb |
764 |
IMYNYPAM |
A |
Mycobacterium tuberculosisTB10.4 4-11 |
H-2Ld |
158 |
MPVGGQSSF |
A |
Mycobacterium tuberculosis Ag85A 70–78 |
Vaccinia Virus
Publications citing Vaccinia Pentamers
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
978 |
ILDDNLYKV |
A |
Vaccinia virus Copenhagen Protein G5 18-26 |
A*02:01 |
703 |
KVDDTFYYV |
A |
Vaccinia virus Host range protein 2 74-82 |
H-2Kb |
733 |
TSYKFESV |
A |
Vaccinia virus WR epitope B8R 20-27 |
Vesicular Stomatitis Virus
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
H-2Kb |
373 |
RGYVYQGL |
A |
VSV NP 52 |
H-2Ld |
622 |
MPYLIDFGL |
A |
VSV N 275-283 |
West Nile Virus
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
A*02:01 |
1320 |
RLDDDGNFQL |
A |
West Nile Virus NY-99 polyprotein precursor (1452-1461) |
A*02:01 |
1327 |
YTMDGEYRL |
A |
West Nile virus NY-99 polyprotein precursor 2023-2031 |
A*02:01 |
1322 |
ATWAENIQV |
A |
West Nile virus NY-99 polyprotein precursor 3390-3398 |
H-2Db |
663 |
LGMSNRDFL |
A |
West Nile Virus polyprotein 294-302 |
Yellow Fever
ALLELE |
PEPTIDE CODE |
PEPTIDE SEQUENCE |
Stock/
|
EPITOPE ORIGIN |
H-2Kb |
1182 |
ATLTYRML |
A |
Yellow Fever Virus 17D polyprotein 268-275 |
